Mounjaro®
Starting from £179.99/mo
Start journey Learn moreYes, weight loss injections genuinely work — but with an important qualifier. The medicines licensed in the UK for this purpose, tirzepatide (Mounjaro) and semaglutide (Wegovy), have been tested in large, well-designed clinical trials and produced meaningful, sustained weight loss in the majority of participants. In SURMOUNT-1, adults taking tirzepatide lost an average of around 20% of their body weight over 72 weeks, results that prompted NICE to recommend tirzepatide for eligible adults in December 2024. They are prescription-only medicines, which means a qualified clinician has to assess your medical history before any treatment begins. No injection works identically for everyone, and results depend on the dose reached, consistency, and the lifestyle changes you make alongside treatment.
At your door the next working day.
Free, tracked, plain packaging.
BMI isn't the whole story, but it's where clinicians start. Check yours in ten seconds — nothing is stored, nothing is shared.
Ten seconds. Private — nothing is stored or shared.
Your result updates live in the card alongside.
Your result
Your BMI is
—
which is in the healthy weight range
Start journeyBMI doesn't determine eligibility — only a clinician can assess whether treatment is right for you.
The problem
The nume way
clinician review. Free next working day delivery.
How it works
Tell us about your health, history and goals. Free, online, and confidential — no commitment, no waiting room.
Our team reviews your health the same day — never an algorithm, and approves your treatment there and then if eligible.
Order by 12pm, dispatched same day, delivered free the next working day — the nume Promise.
The process starts well before any injection. Because tirzepatide and semaglutide are prescription-only medicines under the Human Medicines Regulations, a clinician has to review your health before anything is dispensed. At a regulated online pharmacy, that means completing a medical consultation, your answers are read by a real clinician, not processed by software. At nume, a GPhC-registered Independent Prescriber reviews each consultation personally, the same day.
The prescriber is looking at your BMI, your weight-related health conditions, your current medicines, and any contraindications in your history. Adults with a BMI of 30 or above are generally eligible for the licensed medicines, as are those with a BMI of 27 or above alongside a condition such as high blood pressure, high cholesterol or type 2 diabetes. A high BMI alone does not guarantee approval, the full clinical picture matters. Learn more about who these injections are typically suitable for.
Once approved, the prescription is issued and the medicine is dispensed from a GPhC-registered pharmacy. Your first pen arrives via DPD in plain, unbranded packaging, with a tracking link sent to your phone before it leaves the building.
Mounjaro and Wegovy are both once-weekly subcutaneous injections given at home, into the abdomen, thigh or upper arm, rotating the site each week. The mechanism of action is what sets these medicines apart from older approaches. They mimic gut hormones that signal fullness to the brain, slow gastric emptying so a smaller meal satisfies for longer, and in the case of tirzepatide, act on two hormone receptors simultaneously (GIP and GLP-1). The effect is a genuine biological shift in appetite, not willpower.
Most people notice they feel full sooner within the first week or two, often before the scales show much change. Gastrointestinal side effects (nausea, loose stools, constipation or indigestion) are common at the start or after a dose increase, and usually settle within a week or two as the body adjusts. They are the most frequently reported reason for pausing a dose increase, so prescribers build in gradual titration steps for exactly this reason. The NHS medicines page for tirzepatide covers the side-effect profile in full, and it is worth reading before starting.
Treatment starts at a low dose (2.5mg for tirzepatide) which exists primarily to let the body acclimatise, not to drive weight loss. The prescriber typically increases the dose every four weeks, subject to how it is being tolerated, up to the highest dose that suits you. Most of the headline trial results reflect what participants achieved at maintenance doses over many months.
For a realistic picture: how quickly weight loss injections work varies between individuals, but STEP 1 (the pivotal semaglutide trial, published in the New England Journal of Medicine) showed that participants lost roughly half their eventual total weight loss in the first six months, with results continuing to accumulate through to 68 weeks. Tirzepatide's SURMOUNT-1 data followed a similar curve. The implication is that patience, and staying on the titration schedule your prescriber sets, is part of what makes these medicines work. Stopping early, or missing doses, blunts the outcome. If you are curious about how the results compare to older options or alternative approaches, our weight loss overview sets out the broader picture.
A common question is whether these injections specifically reduce fat around the abdomen. There is no evidence they target one area preferentially, belly fat and weight loss injections is a topic worth reading on its own terms, but the short answer is that overall weight loss tends to reduce visceral fat proportionally, which is clinically meaningful for cardiovascular risk. Another question is whether vitamin B12 injections do the same job: they do not. B12 injections have no evidence base for weight loss and are not in the same category as licensed GLP-1 medicines.
Thinking about cost alongside effectiveness is reasonable. Private treatment is an investment, and our guide to what weight loss injections cost in the UK lays out what typical pricing includes and what to watch for. One cost-related thing worth flagging: the MHRA has warned about counterfeit weight loss pens sold online, including fake pens that have contained insulin. Purchasing from a pharmacy you can verify on the GPhC register is the single most important safety step you can take.
If you have read this far and want to find out whether treatment is right for you, our prescribers are the right next step. Start your free consultation and a clinician will review your details the same day.
The people
Superintendent Pharmacist (GPhC No. 2217101)
Accountable for the safe running of our registered pharmacy, from every dispensing check to every dispatch.
Clinical Lead (GPhC No. 2231744)
Sets our clinical standards and checks everything we publish against current MHRA guidance.
Independent Prescriber (GPhC No. 2084501)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.
Independent Prescriber (GPhC No. 2083426)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.